Each week we highlight five things affecting the life sciences industry. Here’s the latest.
- The U. S. Food and Drug Administration is using its Technology-Enabled Meaningful Patient Outcomes pilot to accelerate access to digital health tools by allowing select companies to distribute devices to Medicare patients without prior FDA authorization, while requiring manufacturers to collect real-world performance data after deployment.
- According to Endpoints News, this reflects a broader FDA shift toward accepting greater uncertainty before products reach patients, particularly for digital health and AI-enabled medical devices, relying more heavily on post-market monitoring. While the approach could speed innovation and patient access, critics warn it may expose patients and taxpayers to ineffective or insufficiently evaluated technologies.
- The White House has nominated Heidi Overton, M.D., Ph.D., currently the deputy director of the White House Domestic Policy Council, to become the next FDA commissioner. Overton previously worked as a White House fellow, held leadership roles at the America First Policy Institute, and has been viewed as a leading candidate since the former commissioner departed in May.
- If confirmed by the Senate, Overton would take over an FDA focused on accelerating medical innovation and drug development. Administration officials expect her to advance FDA modernization, provide faster access to treatments, and increase transparency and science-based decision-making, according to Fierce Pharma.
- The FDA has released a discussion paper and is seeking public feedback on how to regulate generative artificial intelligence-enabled medical devices, recognizing both the technology’s potential to improve patient care and its unique risks, such as hallucinations, variable outputs and unclear performance boundaries.
- According to Medtech Dive, the proposed framework includes a risk-based classification model, competency-based premarket testing and robust post-market monitoring.
- The FDA has approved the first standalone robotic blood-draw device in the U.S., allowing the device system to autonomously perform the entire venipuncture process as long as there is oversight from a phlebotomist. The approval is intended to help address the ongoing shortage of trained phlebotomists.
- Fierce Biotech reports that the device uses near-infrared imaging and ultrasound to identify veins and achieved a 94.5% first-stick success rate in clinical testing. Following two years of use in Europe and a $70 million Series B financing, the medical device company plans to scale its manufacturing and expand commercialization in the U.S. market.
- The European Medicines Agency validated the marketing authorization application for a Lyme disease vaccine candidate, allowing formal regulatory assessment to begin, reports RTT News.
- The program remains one of the most advanced vaccine efforts targeting Lyme disease, an area with significant unmet medical need in Europe and North America.
For more insights in life sciences, check out RSM’s industry outlook.